Median overall survival was not reached in either group ( hazard ratio for death with crizotinib , 0.82 ; 95 % CI , 0.54 to 1.26 ; P = 0.36 ) ; the probability of 1-year survival was 84 % with crizotinib and 79 % with chemotherapy .